Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Cushing Syndrome 6Hypertension 5Diabetes Mellitus, Type 2 5ACTH Syndrome, Ectopic 5Pituitary ACTH Hypersecretion 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Adrenocortical Carcinoma 3Adrenal Cortex Neoplasms 3Peritoneal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Processes 1Ovarian Diseases 1Neoplasms by Site 1Hyperglycemia 1Glucose Intolerance 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Endocrine System Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Adrenocortical Hyperfunction 1Adrenal Gland Diseases 1Adenocarcinoma 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × relacorilant × Clear all
NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Corcept Therapeutics

Phase 1/2 Completed
85 enrolled 24 charts
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡